Incannex Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment Mar 15, 2023 | ASX News, Incannex Healthcare (ASX:IHL)